IDE and Alzheimer disease: In vivo, the PPARγ activator rosiglitazone increased the expression level of IDE and decreased Aβ levels in a mixed mouse model of AD and type 2 diabetes and alleviated the spatial learning and recognition impairments in these mice (Li et al., 2018).